Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.81 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.81 |
| ▸ | HSD17B1 | P14061 | 7/20 | 0.81 |
| ▸ | STS | P08842 | 5/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | MAPT | P10636 | 2/20 | 0.81 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.81 |
| ▸ | SHBG | P04278 | 1/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | PGR | P06401 | 1/20 | 0.81 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.81 |
| ▸ | AR | P10275 | 1/20 | 0.81 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.81 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.81 |
| ▸ | SNCA | P37840 | 1/20 | 0.81 |
| ▸ | HTR2B | P41595 | 1/20 | 0.81 |
| ▸ | BLM | P54132 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estrone SCHEMBL6120389 | 0.93 | HSD17B1 (0.71) | CYP19A1HSD17B1STSCYP3A4LMNA | |
| Estrone SCHEMBL603955 | 0.90 | STS (0.91) | CYP19A1HSD17B1STSCYP3A4LMNA | |
| Estrone SCHEMBL13153301 | 0.90 | CYP19A1 (1.00) | CYP19A1HSD17B1STSCYP3A4LMNA | |
| Estrone SCHEMBL12822081 | 0.90 | CYP19A1 (1.00) | CYP19A1HSD17B1STSCYP3A4LMNA | |
| Estrone SCHEMBL31398229 | 0.90 | CYP19A1 (1.00) | CYP19A1HSD17B1STSCYP3A4LMNA | |
| Estrone SCHEMBL12054811 | 0.90 | CYP19A1 (1.00) | CYP19A1HSD17B1STSCYP3A4LMNA | |
| Estrone SCHEMBL157262 | 0.90 | CYP19A1 (1.00) | CYP19A1HSD17B1STSCYP3A4LMNA | |
| Estrone SCHEMBL15079288 | 0.90 | CYP19A1 (1.00) | CYP19A1HSD17B1STSCYP3A4LMNA | |
| Estrone SCHEMBL7831317 | 0.90 | CYP19A1 (1.00) | CYP19A1HSD17B1STSCYP3A4LMNA | |
| Estrone SCHEMBL5028951 | 0.90 | CYP19A1 (1.00) | CYP19A1HSD17B1STSCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317462-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | ACRUX DDS PTY LTD. (AU) | 2013-11-28 | — | — | US | claimed |
| US-20100279988-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | ACRUX DDS PTY LTD. | 2010-11-04 | — | — | US | claimed |
| EP-2214643-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | Acrux DDS Pty Ltd (AU) | 2010-08-11 | — | — | EP | claimed |
| US-20100041906-A1 | METHOD FOR THE PRECIPITATION OF ORGANIC COMPOUNDS | FUJI-FILM MANUFACTURING EUROPE B.V. | 2010-02-18 | — | — | US | claimed |
| WO-2009055859-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | ACRUX DDS PTY LTD (AU) | 2009-05-07 | — | — | WO | claimed |
| EP-1976608-A1 | METHOD FOR THE PRECIPITATION OF ORGANIC COMPOUNDS | FUJIFILM Manufacturing Europe B.V. (NL) | 2008-10-08 | — | — | EP | claimed |
| WO-2007086735-A1 | METHOD FOR THE PRECIPITATION OF ORGANIC COMPOUNDS | FUJIFILM MANUFACTURING EUROPE B.V. (NL) | 2007-08-02 | — | — | WO | claimed |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | VAN BOGAERT GINA (BE) | 2026-01-15 | — | — | US | disclosed |
| CN-119707610-A | Chiral nitrile compound and preparation method thereof | 安徽中医药大学 | 2025-03-28 | — | — | CN | disclosed |
| US-20250090479-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | IIera Derm LLC | 2025-03-20 | — | — | US | disclosed |
| US-12233143-B2 | Topical compositions containing rose oil and cannabidiol and methods of making and using the same | JLABS Beauty LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-12194003-B2 | Compositions for treating acne and dermatological conditions | Ilera Derm LLC (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240130980-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | Ilera Derm LLC | 2024-04-25 | — | — | US | disclosed |
| WO-1999030620-A1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0901793-A1 | Thermal preactivation of gaseous precursor filled compositions | IMARX PHARMACEUTICAL CORP. (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5877216-A | ADMINISTERING VASODILATING AGENT CONTAINING PROSTAGLANDINS | VIVUS, INCORPORATED (US) | 1999-03-02 | — | — | US | disclosed |
| WO-1998050041-A1 | NOVEL PRODRUGS COMPRISING FLUORINATED AMPHIPHILES | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998050040-A1 | NOVEL LIPID SOLUBLE STEROID PRODRUGS | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
| US-4438139-A | MADE OF POLYVINYL ALCOHOL AND POLYVINYL PYRROLIDONE, SUSTAINED RELEASE | KEY PHARMACEUTICALS, INC. (US) | 1984-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279988-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | SHBG, PGR, NR5A1 | ESR1 14/4885CYP19A1 11/4885HSD17B1 37/4885 |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | NR5A1, SHBG, GNRHR | ESR1 188/4885CYP19A1 13/4885HSD17B1 30/4885 |
| US-20250090479-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | COQ8A, ATP5ME, AGK | ESR1 1283/4885CYP19A1 320/4885HSD17B1 709/4885 |
| US-12233143-B2 | Topical compositions containing rose oil and cannabidiol and methods of making and using the same | RXRG, CNR2, CUTA | ESR1 2115/4885CYP19A1 1180/4885HSD17B1 501/4885 |
| US-20240130980-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | COQ8A, ATP5ME, AGK | ESR1 1283/4885CYP19A1 320/4885HSD17B1 709/4885 |
| US-20130317462-A1 | TRANSDERMAL DELIVERY SYSTEM FOR HORMONES AND STEROIDS | SHBG, PGR, NR5A1 | ESR1 14/4885CYP19A1 11/4885HSD17B1 37/4885 |
| US-12194003-B2 | Compositions for treating acne and dermatological conditions | COQ8A, ATP5ME, AGK | ESR1 1283/4885CYP19A1 320/4885HSD17B1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.